Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Influence of sample centrifugation on plasma platelet count and activated partial thromboplastin time using patient samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term patient-important outcomes after septic shock: a protocol for 1-year follow-up of the CLASSIC-trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Usefulness of layer-specific strain in diagnosis of coronary artery disease in patients with stable angina pectoris

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial—Protocol and statistical analysis plan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prognostic value of left atrial strain in predicting cardiovascular morbidity and mortality in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) predict outcome in patients with acute coronary syndrome (ACS). Unfortunately, administration of heparin to patients with ACS increases circulating PAPP-A, probably by a detachment of PAPP-A from cell surfaces, inducing a considerable bias when using PAPP-A as a biomarker. It remains unknown whether PAPP-A-derived N- and C-terminal fragments of insulin-like growth factor binding protein-4 (NT-IGFBP-4/CT-IGFBP-4) are acutely affected by the increase in PAPP-A.

METHODS: We prospectively included 78 patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). Prior to PCI, patients were injected with 10,000IU of unfractionated heparin (UFH). Blood samples were collected immediately before PCI, but after UFH-injection, immediately after PCI and on day 1 and day 2. Plasma IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 levels were determined by specific, novel immunoassays, and PAPP-A and IGF-I by commercial immunoassays.

RESULTS: Plasma PAPP-A was strongly elevated upon STEMI, UFH-administration and PCI with mean concentrations (95%-confidence interval) pre-PCI, post-PCI, day 1, and day 2 of 13.0 (11.2;15.2), 14.8 (13.1;16.8), 1.03 (0.90;1.18), and 1.08 (0.92;1.28) μg/L, respectively (p<0.0001). Pre-PCI concentrations of IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 were 154 (142;166), 53 (47;60) and 136 (122;150) μg/L, and levels were unaltered post-PCI. Concentrations increased on day 1 by 63 (43;87)%, 69 (36;110)%, and 47 (21;79)%, respectively (p<0.0001), i.e. at a time point when PAPP-A levels had normalized.

CONCLUSION: Plasma IGFBP-4-fragment levels are not acutely altered in patients with STEMI treated with UFH and PCI. Thus, they possess potentials as prognostic markers in ACS patients.

OriginalsprogEngelsk
TidsskriftClinical Biochemistry
Vol/bind48
Udgave nummer4-5
Sider (fra-til)322-8
Antal sider7
ISSN0009-9120
DOI
StatusUdgivet - mar. 2015

ID: 45324944